Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 07:56:53 01/07/2024 pm IST			5-day change	1st Jan Change
69.51 ^USD	+1.31%		-1.40%	-13.91%

27/06	Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia	CI
26/06	Redburn Atlantic Adjusts Price Target on Gilead Sciences to $119 From $117	MT

Gilead, Kite in process of pausing Twitter advertising

November 07, 2022 at 10:27 pm IST

(Reuters) - Gilead Sciences Inc said on Monday the company and its unit Kite were in the "process of pausing advertising" on Twitter, after Elon Musk completed his takeover of the social media company.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Krishna Chandra Eluri)

Latest news about Gilead Sciences, Inc.

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia	27/06	CI
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $119 From $117	26/06	MT
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer	25/06	CI
Jefferies Adjusts Price Target on Gilead Sciences to $85 From $80	24/06	MT
Tech overload on Wall Street	21/06
Wall Street set for muted open as investors await business survey data	21/06	RE
Nvidia Slide Stifles US Equity Futures Pre-Bell	21/06	MT
Top Premarket Gainers	21/06	MT
Wall Street futures edge lower ahead of business survey data	21/06	RE
Equity Markets Close Mixed as Investors Weigh Economic Data	21/06	MT
Equity Markets Close Mixed After Macro Data	21/06	MT
Health Care Stocks Rise Behind Gilead -- Health Care Roundup	21/06	DJ
US Equities Markets Close Mixed Thursday as Markets Parse Latest Economic Data	21/06	MT
Sector Update: Health Care Stocks Higher Late Afternoon	21/06	MT
Sector Update: Health Care Stocks Mixed Thursday Afternoon	20/06	MT
Equity Markets Mixed as Traders Weigh Macro Data	20/06	MT
Sliding Technology Stocks Push S&P 500, Nasdaq Composite Lower	20/06	MT
Sector Update: Health Care	20/06	MT
Gilead Sciences' Twice-Yearly Shot Prevents 100% of HIV Cases in Trial, Shares Jump	20/06	MT
US Benchmark Stock Indexes Mixed in Midday Trading	20/06	MT
Gilead Sciences' Lenacapavir Shows 100% Efficacy, Superiority to Truvada For HIV Prevention	20/06	MT
Gilead Sciences HIV Prevention Treatment Shows 100% Effectiveness in Phase 3 Trial	20/06	DJ
Gilead's long-acting HIV drug superior to daily pill Truvada in study	20/06	RE
Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial	20/06	CI
Assembly Biosciences, Inc. announced that it has received $2.77507 million in funding from Gilead Sciences, Inc.	17/06	CI

Chart Gilead Sciences, Inc.

Duration

Period

More charts

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

Pharmaceuticals

Calendar

09/08/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Gilead Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

68.61 USD

Average target price

82.97 USD

Spread / Average Target

+20.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GILEAD SCIENCES, INC.	-13.91%	8.55TCr
ELI LILLY AND COMPANY	+55.52%	82TCr
NOVO NORDISK A/S	+43.39%	64TCr
JOHNSON & JOHNSON	-5.42%	35TCr
MERCK & CO., INC.	+17.94%	31TCr
ABBVIE INC.	+11.17%	30TCr
ASTRAZENECA PLC	+16.74%	24TCr
ROCHE HOLDING AG	+2.54%	22TCr
NOVARTIS AG	+14.14%	22TCr
AMGEN INC.	+9.77%	17TCr

Other Pharmaceuticals

Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Gilead, Kite in process of pausing Twitter advertising

EPS Revisions